ARAVIVE, INC Current Ratio 2013-2021 | ARAV

ARAVIVE, INC current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
ARAVIVE, INC Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.08B $0.01B 6.87
2021-03-31 $0.08B $0.01B 8.95
2020-12-31 $0.06B $0.01B 6.52
2020-09-30 $0.06B $0.01B 11.37
2020-06-30 $0.06B $0.01B 13.52
2020-03-31 $0.06B $0.01B 12.36
2019-12-31 $0.07B $0.01B 13.73
2019-09-30 $0.05B $0.01B 7.59
2019-06-30 $0.05B $0.01B 11.28
2019-03-31 $0.06B $0.01B 7.78
2018-12-31 $0.06B $0.00B 29.96
2018-09-30 $0.06B $0.00B 20.16
2018-06-30 $0.07B $0.00B 16.95
2018-03-31 $0.08B $0.00B 21.26
2017-12-31 $0.08B $0.01B 14.61
2017-09-30 $0.12B $0.08B 1.53
2017-06-30 $0.16B $0.07B 2.39
2017-03-31 $0.18B $0.06B 3.27
2016-12-31 $0.21B $0.06B 3.77
2016-09-30 $0.16B $0.05B 3.02
2016-06-30 $0.14B $0.01B 16.98
2016-03-31 $0.16B $0.01B 16.63
2015-12-31 $0.19B $0.01B 20.91
2015-09-30 $0.20B $0.01B 27.16
2015-06-30 $0.22B $0.01B 29.91
2015-03-31 $0.23B $0.01B 29.98
2014-12-31 $0.17B $0.01B 24.98
2014-09-30 $0.19B $0.00B 43.06
2014-06-30 $0.20B $0.01B 38.15
2014-03-31 $0.21B $0.01B 37.78
2013-12-31 $0.01B $0.00B 3.58
2013-09-30 $0.00B 0.00
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B $0.01B 0.31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.076B $0.006B
Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76